Oneview Healthcare Chess Depository Interests repr 1 (ONE) AI Stock Analysis

• Market Cap: AU$189.48M
• Dividend Yield: N/A
• Average Volume (3M): 290.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: 5.87%
• EPS Growth: 4.06%
• Country: AU
• Employees: 96
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.03
• Shares Outstanding: 763,852,230
• 10 Day Avg. Volume: 378,412
• 30 Day Avg. Volume: 290,339
• PEG Ratio: -0.52
• Price to Book (P/B): 5.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.45
• Price Target Upside: 78.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: AU$0.50 ▲(100.00%Upside)

Oneview Healthcare's overall score is impacted heavily by its financial struggles, with persistent net losses and negative cash flows being major issues. Technical indicators are neutral, providing little support for a positive outlook. The poor valuation metrics further underscore the stock's challenges.

Oneview Healthcare Chess Depository Interests repr 1 Business Overview & Revenue Model

Company Description

Oneview Healthcare PLC develops and sells software and related consultancy services for the healthcare sector in Ireland, the United States, Australia, Asia, and the Middle East. The company operates Care Experience Platform (CXP) Cloud Start that allows customers to implement critical digital engagement capabilities across their entire enterprise; CXP Cloud Enterprise, which gives patients and their families the ability to communicate virtually with healthcare teams along with access to education and health information; and CXP Enterprise On-Prem that meets enterprise needs across various types of facilities from new construction to existing hospitals with legacy wiring. It also provides empower patients and families, manage patient experience, deliver virtual care, digital door sign, and patient communication board solutions. The company was founded in 2008 and is based in Dublin, Ireland.

How the Company Makes Money

Oneview Healthcare generates revenue through the sale and subscription of its software platforms to hospitals, healthcare facilities, and aged care providers. The company offers a range of customizable solutions tailored to meet the specific needs of its clients, often on a subscription basis that ensures recurring revenue. Additionally, Oneview may engage in partnerships with healthcare institutions and technology providers to expand its service offerings and integrate its technologies into broader healthcare ecosystems, further driving sales and adoption of its platforms.

Oneview Healthcare Chess Depository Interests repr 1 Financial Statement Overview

Summary

Oneview Healthcare faces significant financial challenges, with persistent net losses and negative cash flows. Despite slight improvements in revenue and equity, operational inefficiencies and reliance on external financing are major concerns.

Income Statement

The company has struggled with profitability, evident from consistent negative EBIT and net income figures over recent years. Revenue has shown modest growth, with a 5.3% increase from 2023 to 2024, but margins remain under pressure. The Gross Profit Margin improved slightly, indicating some operational efficiency, yet the persistent net losses hinder overall performance.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, reflecting relatively low leverage. However, the company's equity ratio has been fluctuating, indicating instability in asset financing. Although stockholders' equity has grown, it remains susceptible to ongoing net losses. The overall equity position is improving but remains fragile.

Cash Flow

Cash flow from operations is consistently negative, which, combined with capital expenditures, results in negative free cash flow. There is a reliance on financing activities to support cash flow, which could pose risks if external funding becomes less available. The ratio of operating cash flow to net income indicates that cash generation efficiency is low.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.89M	9.40M	8.92M	9.73M	7.10M
Gross Profit	6.67M	6.16M	5.35M	5.31M	4.72M
EBITDA	-11.26M	-7.88M	-15.38M	-7.42M	-8.18M
Net Income	-10.84M	-8.93M	-10.87M	-8.19M	-9.45M
Balance Sheet
Total Assets	25.96M	21.92M	12.75M	21.09M	14.25M
Cash, Cash Equivalents and Short-Term Investments	13.83M	11.55M	6.41M	15.18M	6.80M
Total Debt	1.15M	935.32K	543.01K	1.20M	1.51M
Total Liabilities	12.71M	12.78M	10.50M	11.19M	10.18M
Stockholders Equity	13.25M	9.14M	2.26M	9.90M	4.07M
Cash Flow
Free Cash Flow	-10.52M	-7.79M	-10.24M	-4.09M	-7.94M
Operating Cash Flow	-10.47M	-7.26M	-10.20M	-4.03M	-7.69M
Investing Cash Flow	-459.78K	-521.38K	-44.52K	-65.26K	-249.35K
Financing Cash Flow	13.14M	13.04M	-100.11K	12.22M	4.95M

Oneview Healthcare Chess Depository Interests repr 1 Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ONE, the sentiment is Negative. The current price of 0.25 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.27, and below the 200-day MA of 0.30, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.91 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ONE.

Oneview Healthcare Chess Depository Interests repr 1 Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥347.63B	11.07	-2.99%	2.55%	11.77%	-10.16%
ONE	46 Neutral	AU$189.48M	―		―	5.87%	4.06%
COGZF	―	$201.06M	24.24	17.87%	―	―	―
TDMMF	―	$57.34M	―	-9.88%	―	―	―
BMT	55 Neutral	AU$78.45M	―	-11.80%	―	14.56%	13.36%
PCK	55 Neutral	AU$71.84M	―	-457.46%	―	21.93%	10.34%
ALC	53 Neutral	AU$147.72M	―	-5.63%	―	-11.96%	7.50%

Oneview Healthcare Chess Depository Interests repr 1 Corporate Events

Oneview Healthcare PLC Announces Quotation of CHESS Depositary Interests

Oneview Healthcare PLC has announced the quotation of 421,666 CHESS Depositary Interests on the Australian Securities Exchange, effective June 19, 2025. This move indicates the company’s strategic effort to enhance its market presence and provide liquidity options for its securities, potentially impacting its operational capabilities and stakeholder interests positively.

The most recent analyst rating on (AU:ONE) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare PLC Announces Quotation of New Securities

Oneview Healthcare PLC announced the quotation of 1,232,788 CHESS Depositary Interests on the Australian Securities Exchange, marking a significant step in its strategic financial operations. This move is expected to enhance the company’s market presence and provide greater flexibility in its capital management, potentially benefiting stakeholders and reinforcing its position in the healthcare technology sector.

The most recent analyst rating on (AU:ONE) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Reports Strong Q1 2025 with Strategic Expansions and Innovations

Oneview Healthcare PLC reported a net cash outflow of €1.6 million for Q1 2025, with strong customer receipts inflows of €4.2 million, reflecting improved financial performance compared to the previous year. The company is actively expanding its market presence through strategic partnerships and product innovations, including the launch of its AI-driven Virtual Patient Assistant, Ovie. The company is also progressing with significant deployment projects and is in contract negotiations with major healthcare systems, positioning itself for continued growth despite potential tariff impacts.